Valeant sells iNova Pharmaceuticals for $930M — 4 insights

Valeant Pharmaceuticals sold its iNova Pharmaceuticals business to a company jointly owned by Pacific Equity Partners and The Carlyle Group for $930 million.

Here's what you should know:

1. Valeant is using the $920 million to repay term loan debt.

2. Valeant also announced it would use operational cash to repay an additional $100 million in outstanding debt.

3. Valeant CEO Joseph Papa believes when the company completes the sale of its Obagi Medical Products Business, Valeant will exceed its August 2016 commitment to pay down $5 billion in debt through divestiture proceeds and free cash flow.

4. Mr. Papa said in a release, "As we continue to deliver on our commitments, we will remain focused on investing in our core businesses that will drive growth and where we believe we can make the biggest impact on the lives of patients."

More articles on gastroenterology: 
These 6 conditions denote inadequately prepared bowels
12 statistics on gastroenterologist salary — $357k is median
Florida gastroenterologist innocent in 'rushed colonoscopy' case — 7 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers